Mendus AB (publ) (IMMU.ST)

SEK 8.51

(-1.06%)

Market Cap (In SEK)

428.5 Million

Revenue (In SEK)

28.48 Million

Net Income (In SEK)

-101.61 Million

Avg. Volume

36.51 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.1-11.44
PE
-
EPS
-
Beta Value
0.824
ISIN
SE0005003654
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Erik Manting Ph.D.
Employee Count
-
Website
https://www.mendus.com
Ipo Date
2013-04-22
Details
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.